Exscientia · pitchdeck
Exscientia | Investor Presentation Deck | 75 slides
75 pages · 6 arc beats · 3 loops
Exscientia | Investor Presentation Deck | 75 slides
Exscientia · 2023-08 arc beats above · slides in the middle · loops below · scroll → 3 LOOPS
151015202530354045505560657075
Deck intelligence map
6 coverage by narrative range · generated from this deck JSON
Narrative range 10 total
Metadata
Components
Metrics
Tools
Frameworks
Beats
Loops
Problem 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Agitate 1 slides 100% 1/1 slides 100% 1/1 slides · 2 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides · 2 hits 100% 1/1 slides Solution 1 slides 100% 1/1 slides 100% 1/1 slides · 3 hits — 0/1 slides
— 0/1 slides
100% 1/1 slides 100% 1/1 slides — 0/1 slides
Situation & Context 2 slides 100% 2/2 slides 100% 2/2 slides · 17 hits — 0/2 slides
50% 1/2 slides · 2 hits 50% 1/2 slides 100% 2/2 slides 50% 1/2 slides Evidence & Proof 3 slides 100% 3/3 slides 100% 3/3 slides · 20 hits — 0/3 slides
100% 3/3 slides · 5 hits 66.7% 2/3 slides 100% 3/3 slides — 0/3 slides
Visualization 2 slides 100% 2/2 slides 100% 2/2 slides · 16 hits — 0/2 slides
— 0/2 slides
50% 1/2 slides 100% 2/2 slides — 0/2 slides
Slide inventory
75 every slide · same image gating as the playbook
03
The slide uses a grid of metrics to summarize the company's current status and business model.summarize
04
The slide uses a dual-track timeline (Pipeline Progress vs Platform/Corporate) followed by a list of future goals.plan_implementation
Open slide detailBeat · Situation & Context
06
The central figure represents the patient, with six surrounding nodes representing different technological capabilities.present_solution
Open slide detailBeat · Solution
07
The slide uses a horizontal bar chart representation to show the stage of development for each program.plan_implementation
08
The slide highlights the company's precision medicine approach to drug development.present_solution
09
Uses a concentric circle diagram to categorize partnership benefits.present_solution
10
The slide uses a stepped arrow timeline to show progression from known targets to challenging novel targets.plan_implementation
11
The slide uses a 3x2 grid layout to present quantitative achievements.show_traction
12
Includes footnote regarding fixed term bank deposits and shares outstanding.analyze_data
14
The slide uses a complex diagram combining a linear process flow with a double-loop feedback mechanism (flywheel).present_solution
15
The slide uses a circular process flow to represent a proprietary R&D pipeline.present_solution
16
The slide uses a process flow diagram to illustrate a clinical case study.show_traction
Open slide detailBeat · Evidence & Proof
17
Kaplan-Meier survival analysis showing statistically significant improvement in PFS for matched treatments.show_traction
Open slide detailBeat · Evidence & Proof
18
The slide uses a horizontal process-like layout to showcase four distinct pillars of their R&D engine.present_solution
Open slide detailBeat · Evidence & Proof
19
The slide uses a circular flow diagram to represent the integration of experimental and AI-driven precision medicine.present_solution
20
The slide highlights the integration of various data sources (Knowledge Graphs, Neural Networks, Literature/Patent Databases, Multi-omics, Vector Embedding) intpresent_solution
21
The slide uses a hierarchical clustering heatmap to visualize drug sensitivity across patient samples.frame_problem
22
The slide illustrates a drug discovery workflow using MPO (Multiparameter Optimisation) to balance multiple biological and chemical constraints.present_solution
23
The diagram illustrates a multi-modal AI pipeline for drug discovery.present_solution
24
The slide features a 3D molecular model and a UI overlay displaying various pharmacological parameters (potency, selectivity, stability, etc.) and a merit scorepresent_solution
25
The chart illustrates a Pareto frontier where the AI selects compounds that are not necessarily the highest in potency but provide high information gain.present_solution
26
The slide uses a series of dose-response curves to demonstrate differential drug sensitivity across patient samples.analyze_data
29
The visual depicts a molecular structure, likely representing the drug candidate or its target.show_traction
Open slide detailLoop · Quick Win Big Bet
30
MTD = Maximum Tolerated Dose; ORR = Objective Response Rate; ABS = Adenosine Burden Score.plan_implementation
Open slide detailBeat · Visualization
31
The slide uses a human anatomy diagram to map patient counts to specific disease locations.size_opportunity
Open slide detailBeat · Visualization
32
The slide shows a heatmap of 43 patient samples across different cancer types, correlating ABS with signature scores.present_solution
33
The slide presents two distinct sets of data: a comparative line chart (left) and a series of box-and-whisker plots (right) showing performance across differentanalyze_data
34
The slide uses a combination of bar charts and scatter plots to demonstrate the inverse relationship between ABS and TIS.analyze_data
35
The slide presents two line/box plots showing dose-dependent responses to stabilised adenosine.analyze_data
36
The slide presents two key clinical data plots: a pharmacodynamic correlation (exposure vs inhibition) and a pharmacokinetic profile (concentration over time).show_traction
38
The slide outlines a standard oncology clinical trial design (Dose Escalation to RP2D to Dose Expansion).plan_implementation
39
The slide uses a human anatomy diagram to map specific cancer types to their respective incidence numbers.size_opportunity
40
Includes a biological pathway diagram and a honeycomb-style indication map.size_opportunity
41
The slide uses a three-column layout to define the target product profile (TPP) requirements for a drug candidate.present_solution
42
The table uses a color-coded system (green/yellow/red) to indicate performance against criteria.compare_peers
44
The waterfall plot shows drug response scores across many samples, indicating sensitivity. The right side summarizes findings and the rationale for combination show_traction
45
The slide uses a heatmap to display binary synergy results (Yes/No) across three drug combinations, alongside a bar chart showing single-agent sensitivity.present_solution
46
The slide uses a Venn diagram to illustrate the overlap of gene modulation between peripheral blood and primary tumours, and line charts to show dose-response cpresent_solution
47
The slide features a 3D molecular visualization of the protein target.present_solution
49
The slide uses a traffic-light color coding system to highlight performance against criteria.compare_peers
50
The slide uses a process-flow layout to describe the company's R&D methodology.present_solution
51
The visual background is a stylized molecular structure, emphasizing the biotech/pharma context.show_traction
53
Includes two scientific diagrams illustrating the mechanism of action and brain penetration.present_solution
54
The slide uses a three-column layout to define technical requirements for a drug candidate.present_solution
55
The slide uses a traffic-light color coding system to indicate performance against criteria.compare_peers
56
The slide uses a linear process framework to explain the drug discovery pipeline.present_solution
57
The slide uses a Pareto front to illustrate the trade-off between CNS score and Potency, highlighting the selection of 'unattractive' compounds.present_solution
58
The slide shows two charts: a line chart for tumour volume over time and a dot plot for plasma Pro-GRP concentration.show_traction
59
The slide uses two distinct chart types (dot plot and line chart) to demonstrate the safety profile of a reversible inhibitor.present_solution
60
The chart shows a statistically significant difference (****) between the vehicle control and the treatment groups.show_traction
61
The slide uses a two-column layout to contrast PK data with Toxicology/Safety data.present_solution
62
The slide uses a split-layout to contrast current operational status with high-level program benefits.summarize
63
The slide uses a stylized molecular visualization as a background, typical of biotech pitch decks.show_traction
67
The slide uses a scientific mechanism-of-action argument to establish a competitive moat.present_solution
68
The slide uses a heatmap-style table to compare the company's asset against competitors, with a specific callout box around the UGT1A1 row.compare_peers
69
The slide uses a process-based framework to show how MD and AI are integrated into a drug discovery workflow.present_solution
70
The image shows a protein binding site with color-coded regions (Donor, Apolar, Acceptor) indicating chemical properties.present_solution
71
The chart displays tumour volume over time (D20-D48) with error bars representing standard deviation and statistical significance markers.show_traction
72
The chart shows tumor volume over time (D20-D30), with the combination therapy (teal line) showing a flat growth curve compared to monotherapies and vehicle conpresent_solution